0
0
India’s ambitious National Sickle Cell Anaemia Elimination Mission (NSCEM) is showing remarkable progress just over a year after its launch, rapidly transforming the landscape of sickle cell disease (SCD) diagnosis, management, and prevention across the country.
Widespread Screening and Impact
The mission, which targets 278 districts with a particular focus on tribal populations—who are disproportionately affected by SCD—has already screened over 42 million people in its first year. This figure is more than ten times the annual number of babies screened in the United States and 70 times that of the United Kingdom, highlighting the unprecedented scale of the initiative.
Each day, approximately 2,500 carriers of the sickle cell trait are identified. Although these carriers do not face immediate clinical concerns, their identification is crucial for prevention. They receive education about SCD, access to premarital screening, and genetic counselling to help prevent the transmission of the disease to future generations. All individuals screened are issued standardized, color-coded identity cards that visually indicate their sickle cell status and reproductive risk.
Comprehensive Approach: Prevention, Care, and Research
The NSCEM’s multi-pronged strategy extends well beyond screening:
-
Prevention: Mass immunization campaigns against infections such as Streptococcus pneumoniae and Haemophilus influenzae have improved survival rates. High-risk individuals receive targeted counselling.
-
Prenatal Screening: Advanced prenatal diagnostic techniques like chorionic villus sampling and amniocentesis are offered free of cost to at-risk couples, empowering informed family planning decisions—even in remote areas.
-
Social Support and Legal Protection: The Rights of Persons with Disabilities (RPWD) Act of 2016 covers SCD, providing accommodations in schools and workplaces, financial assistance, and protections against discrimination for those with significant disability.
-
Therapies and Treatment: Hydroxyurea, a disease-modifying drug, is widely available and dispensed free through government health systems. India also boasts 114 Hematopoietic Cell Transplantation (HCT) centers, further expanding access to curative treatments.
-
Research: India is emerging as a hub for SCD clinical trials, with 47 trials registered, including studies on new drugs and gene therapies. The government is investing significantly in developing domestic gene therapy solutions for SCD.
Future Directions
Announced by Prime Minister Narendra Modi in 2023, the NSCEM aims to eliminate SCD as a public health problem by 2047. The mission’s pillars include increasing awareness, universal screening, continuous care, strengthening healthcare infrastructure, and fostering community support. Progress is tracked in real time via a public online portal to ensure efficient resource allocation.
Disclaimer:
This article is based on information provided by HT Brand Studio and does not reflect the journalistic or editorial involvement of Hindustan Times. The information is for general awareness and does not constitute medical advice. For health-related concerns, please consult a registered medical practitioner.
